Abstract
Background: One possible mechanism of chemotherapeutic resistance in patients with metastatic prostate cancer is the overexpression of P-glycoprotein. Additional tumor models are necessary to study this phenomenon. Materials and Methods. Doxorubicin resistant rat prostate cancer cell lines were developed by increasing doxorubicin levels in cell culture. Results: The MDR lines (AT3B-1, AT3B-2, MLLB-1, and MLLB-2) were more resistant to vinblastine compared to controls. When P-glycoprotein was blocked the AT3 MDR lines demonstrated efflux activity. Injection of AT3 MDR lines into rats followed by doxorubicin treatment produced larger tumors compared to the parental controls. Conclusions: MDR rat prostate cancer cells were developed. AT3B-1 and AT3B-2 cell lines have drug efflux pump ability, whereas the MLLB-1 and MLLB-2 may not, suggesting alternative key mechanisms other than P-glycoprotein overexpression. These new cell lines are being used to study chemotherapy resistance in prostate cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4535-4538 |
| Number of pages | 4 |
| Journal | Anticancer research |
| Volume | 17 |
| Issue number | 6 D |
| State | Published - Nov 1997 |
| Externally published | Yes |
Keywords
- AT3
- MAT-Ly-Lu
- Multidrug resistance
- P-glycoprotein
ASJC Scopus subject areas
- Oncology
- Cancer Research